Bracco

Bracco is a nearly century-old, family-owned Italian company that has established itself as a global authority in the diagnostic imaging sector, specifically in contrast media and related medical devices. With a strong commercial footprint generating approximately €2 billion in annual revenue, the company reinvests significantly in R&D to drive innovation in precision diagnostics. Its strategic focus includes expanding its digital and AI-enabled solutions, such as the AiMIFY platform, while maintaining a core portfolio of established imaging agents and pursuing new indications like pediatric use for its novel agent gadopiclenol.

Contrast media molecular design and formulation; AI-powered software (e.g., AiMIFY platform) for diagnostic imaging analysis and workflow; Medical devices for contrast agent delivery (via ACIST Medical Systems).

Bracco competes in a consolidated global market against large, diversified players like Bayer (with its market-leading Gadovist), GE HealthCare, and Guerbet. In the emerging AI radiology software space, it faces competition from both pure-play AI startups and large imaging equipment manufacturers (Siemens Healthineers, Canon Medical) integrating AI into their platforms.